Výsledky vyhledávání

Akademický článek

Retrospective evaluation of the effect of acid suppressant drugs on leukocyte ratios in dogs with mast cell tumors

Autor: Sydney Oberholtzer, Xiaojuan Zhu, Andrea Dedeaux, Olya Martin, Emily N. Gould

Publikováno v: Journal of Veterinary Internal Medicine, Vol 38, Iss 4, Pp 2305-2315 (2024)

Abstract Background Acid suppressant drugs (ASDs) are commonly used to decrease gastric acid production, but some evidence exists that ASDs exert immunomodulatory effects. Such an effect has not been investigated in dogs for which ASDs are routinely

Externí odkaz: https://doaj.org/article/48a94d8ed18048049be5fbac065cebac

Zobrazit plný text záznamu

Supplementary Table 3 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Autor: Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc

Supplementary Table 3 contains a summary of the outcomes, with statistical comparisons, of the dogs enrolled in the SOC clinical trial arm. This includes the DFI and outcomes of the groups of dogs stratified by tumor location and ALP status.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cf79f886bb73370f4df3bf2b203861b
https://doi.org/10.1158/1078-0432.22478240

Zobrazit plný text záznamu

Supplementary Figure 1 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Supplementary Fig. 1 depicts the chronology of clinical trial visits and associated procedures for dogs enrolled in this clinical trial.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e206106b269e032e0544bf85a04ba6
https://doi.org/10.1158/1078-0432.22478255

Zobrazit plný text záznamu

Supplementary Table 2 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Supplementary Table 2 contains the summary comparison of both the Intent-to-treat and Per-protocol analyses of clinical outcomes for dogs enrolled in Standard of Care (SOC) and Standard of Care + sirolimus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22720df435a1efb42466d847b634528d
https://doi.org/10.1158/1078-0432.22478243.v1

Zobrazit plný text záznamu

Data from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Purpose:The mTOR pathway has been identified as a key nutrient signaling hub that participates in metastatic progression of high-grade osteosarcoma. Inhibition of mTOR signaling is biologically achievable with sirolimus, and might slow the outgrowth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84d6627db92e6f7818bf68c257932e98
https://doi.org/10.1158/1078-0432.c.6529898

Zobrazit plný text záznamu

Supplementary Table 4 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Supplementary Table 4 contains a summary of the outcomes, with statistical comparisons, of the dogs enrolled in the SOC + sirolimus clinical trial arm. This includes the DFI and outcomes of the groups of dogs stratified by tumor location and ALP stat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12b4b2bcfb3ae31f8ee4ca6faffb8b03
https://doi.org/10.1158/1078-0432.22478234.v1

Zobrazit plný text záznamu

Supplementary Table 1 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Supplementary Table 1 contains the inclusion and exclusion criteria for pet dogs considered for enrollment into the SOC and SOC + S clinical trial arms.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c8771cb32678faca85f7857e9bfb82e
https://doi.org/10.1158/1078-0432.22478246.v1

Zobrazit plný text záznamu

Supplementary Figure 2 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Supplementary Fig. 2 shows the walk-in pharmacokinetics, both measured results and simulated values, for dogs treated with oral sirolimus in preparation for the definitive adjuvant trial.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0edbd37a95c6642ae6a32b8a9bce281c
https://doi.org/10.1158/1078-0432.22478252

Zobrazit plný text záznamu

Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Autor: Amy K. LeBlanc, Timothy M. Fan, Heather Wilson-Robles, Corey F. Saba, Janean Fidel, Nicole C. Northrup, Annette N. Smith, Michael O. Childress, Shawna Klahn, Jennifer L. Willcox, David M. Vail, William C. Kisseberth, Megan E. Brown, Lisa G. Barber, Erika L. Krick, Haley Leeper, Kristine Burgess, Chand Khanna, Raelene M. Wouda, Susan E. Lana, Nikolaos Dervisis, Olya Martin, Angela L McCleary-Wheeler, Mary Lynn Higginbotham, J. Paul Woods, Jeffrey N. Bryan, Aswini Cherukuri, Steven E. Suter, Stephanie S Lindley, Daniel L. Gustafson, Brandan G Wustefeld-Janssens, Laura E. Selmic, Kristen M. Weishaar, Brian K. Flesner, Christina Mazcko, Jenna H Burton, Erika P. Berger, Sara D. Allstadt, Antonella Borgatti, Jennifer A. Mahoney, Cheryl E. Balkman, Kaitlin M. Curran, Anthony J. Mutsaers, Cheryl A. London

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 11
Clin Cancer Res

Purpose: The mTOR pathway has been identified as a key nutrient signaling hub that participates in metastatic progression of high-grade osteosarcoma. Inhibition of mTOR signaling is biologically achievable with sirolimus, and might slow the outgrowth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::733d5a6dd323a4dc1ec07778b41b81ee
https://escholarship.org/uc/item/68n9j044

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání